Seminars in Hematology
Volume 44, Issue 3 , Pages 157-165 , July 2007

Risks and Benefits of Erythropoiesis-Stimulating Agents in Cancer Management

  • Gernot Beutel

      Affiliations

    • Corresponding Author InformationAddress correspondence to Gernot Beutel, MD, Department of Hematology, Hemostasis, and Oncology, Hannover Medical School, Carl Neuberg Str 1, 30625 Hannover, Germany.
    • ,
  • Arnold Ganser

References 

  1. Ludwig H, Van BS, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P, et al. The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004;40:2293–2306
  2. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst. 1999;91:1616–1634
  3. Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: A systematic review of the literature. Am J Med. 2004;116(suppl 7A):11S–26S
  4. Kaushansky K. Lineage-specific hematopoietic growth factors. N Engl J Med. 2006;354:2034–2045
  5. Wood PA, Hrushesky WJ. Cisplatin-associated anemia: An erythropoietin deficiency syndrome. J Clin Invest. 1995;95:1650–1659
  6. Ludwig H, Strasser K. Symptomatology of anemia. Semin Oncol. 2001;28:7–14
  7. Vogelzang NJ, Breitbart W, Cella D, Curt GA, Groopman JE, Horning SJ, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: Results of a tripart assessment survey (The Fatigue Coalition). Semin Hematol. 1997;34:4–12
  8. Lind M, Vernon C, Cruickshank D, Wilkinson P, Littlewood T, Stuart N, et al. The level of haemoglobin in anaemic cancer patients correlates positively with quality of life. Br J Cancer. 2002;86:1243–1249
  9. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) scale: A new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol. 1997;34:13–19
  10. Ahlberg K, Ekman T, Gaston-Johansson F, Mock V. Assessment and management of cancer-related fatigue in adults. Lancet. 2003;362:640–650
  11. Goodnough LT. Risks of blood transfusion. Anesthesiol Clin North America. 2005;23:241–252
  12. Toy P, Popovsky MA, Abraham E, Ambruso DR, Holness LG, Kopko PM, et al. Transfusion-related acute lung injury: Definition and review. Crit Care Med. 2005;33:721–726
  13. Blajchman MA, Hebert PC. Red blood cell transfusion strategies. Transfus Clin Biol. 2001;8:207–210
  14. Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, et al. Transfusion Requirements in Critical Care Investigators Canadian Critical Care Trials Group A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med. 1999;340:409–417
  15. Simon TL, Alverson DC, AuBuchon J, Cooper ES, DeChristopher PJ, Glenn GC, et al. Practice parameter for the use of red blood cell transfusions: Developed by the Red Blood Cell Administration Practice Guideline Development Task Force of the College of American Pathologists. Arch Pathol Lab Med. 1998;122:130–138
  16. Murphy MF, Wallington TB, Kelsey P, Boulton F, Bruce M, Cohen H, et al. Guidelines for the clinical use of red cell transfusions. Br J Haematol. 2001;113:24–31
  17. D’Andrea AD, Lodish HF, Wong GG. Expression cloning of the murine erythropoietin receptor. Cell. 1989;57:277–285
  18. Koury MJ, Bondurant MC. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science. 1990;248:378–381
  19. Lai PH, Everett R, Wang FF, Arakawa T, Goldwasser E. Structural characterization of human erythropoietin. J Biol Chem. 1986;261:3116–3121
  20. Koury ST, Bondurant MC, Koury MJ. Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization. Blood. 1988;71:524–527
  21. Koury ST, Bondurant MC, Koury MJ, Semenza GL. Localization of cells producing erythropoietin in murine liver by in situ hybridization. Blood. 1991;77:2497–2503
  22. Macdougall IC. CERA (continuous erythropoietin receptor activator): A new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep. 2005;4:436–440
  23. Goldwasser E, Kung CK, Eliason J. On the mechanism of erythropoietin-induced differentiation. 13. The role of sialic acid in erythropoietin action. J Biol Chem. 1974;249:4202–4206
  24. Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol. 2003;31:290–299
  25. Waltzman R, Croot C, Justice GR, Fesen MR, Charu V, Williams D. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy. Oncologist. 2005;10:642–650
  26. Morreale A, Plowman B, DeLattre M, Boggie D, Schaefer M. Clinical and economic comparison of epoetin alfa and darbepoetin alfa. Curr Med Res Opin. 2004;20:381–395
  27. Cazzola M, Beguin Y, Kloczko J, Spicka I, Coiffier B. Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol. 2003;122:386–393
  28. Procrit (epoetin alfa) full prescribing information: http://www.orthobiotech.com/common/prescribing_information/PROCRIT/PDF/ProcritBooklet.pdf. Accessed March 1, 2007
  29. Aranesp (darbepoetin alfa) prescribing information: http://www.aranesp.com/pdf/aranesp_PI.pdf; accessed May 6, 2007
  30. NeoRecormon (epoetin beta) Roche UK package leafeat: http://www.rocheuk.com/productdb/documents/rx/pil/neorecormon_pfs_pil.pdf; accessed January 1, 2007
  31. Glaspy J, Vadhan-Raj S, Patel R, Bosserman L, Hu E, Lloyd RE, et al. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: The 20030125 Study Group Trial. J Clin Oncol. 2006;24:2290–2297
  32. Storring PL, Tiplady RJ, Gaines Das RE, Stenning BE, Lamikanra A, Rafferty B, et al. Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol. 1998;100:79–89
  33. Kwan JT, Pratt RD Epoetin Delta Study Group. Epoetin delta, erythropoietin produced in a human cell line, in the management of anaemia in predialysis chronic kidney disease patients. Curr Med Res Opin. 2007;23:307–311
  34. Rizzo JD, Lichtin AE, Woolf SH, Seidefeld J, Bennett CL, Cella D, et al. Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood. 2002;100:2303–2320
  35. Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer. 2007;43:258–270
  36. NCCN Clinical Practice Guidelines in Oncology v.2.2007: Cancer- and Treatment-Related Anemia. http://www.nccn.org/professionals/physician_gls/PDF/anemia.pdf; accessed May 6, 2007
  37. Quirt I, Bramwell V, Charette M, Oliver T, Systemic Treatment Disease Site Group: The role of erythropoietin in the management of cancer patients with non-hematologic malignancies receiving chemotherapy. http://www.cancercare.on.ca/pdf/pebc12-1f.pdf; accessed May 6, 2007
  38. Seidenfeld J, Piper M, Flamm C, Hasselblad V, Armitage JO, Bennett CL, et al. Epoetin treatment of anemia associated with cancer therapy: A systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst. 2001;93:1204–1214
  39. Bottomley A, Thomas R, Van SK, Flechtner H, Djulbegovic B. Human recombinant erythropoietin and quality of life: A wonder drug or something to wonder about?. Lancet Oncol. 2002;3:145–153
  40. Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 2006;3:CD003407
  41. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001;19:2865–2874
  42. Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, et al. Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006;98:708–714
  43. Clark O, Adams JR, Bennett CL, Djulbegovic B. Erythropoietin, uncertainty principle and cancer related anaemia. BMC Cancer. 2002;2:23
  44. Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennet C, et al. Erythropoietin for patients with malignant disease. Cochrane Database Syst Rev. 2004;CD003407
  45. Smith KJ, Bleyer AJ, Little WC, Sane DC. The cardiovascular effects of erythropoietin. Cardiovasc Res. 2003;59:538–548
  46. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584–590
  47. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol. 2003;4:459–460
  48. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–2098
  49. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–2084
  50. DAHANCA: Danish Head and Neck Cancer Group. http://frejacms.au.dk/dahanca/get_media_file.php?mediaid=125; accessed May 7, 2007
  51. FDA Safety Information and Adverse Event Reporting Program: 2007 Safety Alert: Aranesp (darbepoetin alfa). http://www.fda.gov/Medwatch/safety/2007/Aranesp_DHCP_012707.htm; accessed May 6, 2007
  52. Wright JR, Ung YC, Julian JA, Pritchard KI, Whelan TJ, Smith C, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol. 2007;25:1027–1032
  53. FDA Information for Healthcare Professionals: Information in Erythopoiesis Stimulating Agents (ESA) (market as Procrit, Epogen, and Aranesp) 11/16/2006, Updated 2/16/2007 and 3/9/2007. http://www.fda.gov/cder/drug/InfoSheets/HCP/RHE2007HCP.htm; accessed March 9, 2007
  54. Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 2003;362:1255–1260
  55. Rossert J, Casadevall N, Eckardt KU. Anti-erythropoietin antibodies and pure red cell aplasia. J Am Soc Nephrol. 2004;15:398–406
  56. Locatelli F, Del VL. Pure red cell aplasia secondary to treatment with erythropoietin. J Nephrol. 2003;16:461–466
  57. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 2002;346:469–475
  58. Eckardt KU, Casadevall N. Pure red-cell aplasia due to anti-erythropoietin antibodies. Nephrol Dial Transplant. 2003;18:865–869
  59. Peces R, de la Torre M, Alcazar R, Urra JM. Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anemia. N Engl J Med. 1996;335:523–524
  60. Gershon SK, Luksenburg H, Cote TR, Braun MM. Pure red-cell aplasia and recombinant erythropoietin. N Engl J Med. 2002;346:1584–1586
  61. Verhelst D, Rossert J, Casadevall N, Kruger A, Eckardt KU, Macdougall IC. Treatment of erythropoietin-induced pure red cell aplasia: A retrospective study. Lancet. 2004;363:1768–1771
  62. Schellekens H. Immunogenicity of therapeutic proteins: Clinical implications and future prospects. Clin Ther. 2002;24:1720–1740
  63. Bennett CL, Luminari S, Nissenson AR, Tallman MS, Klinge SA, McWilliams N, et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med. 2004;351:1403–1408
  64. Heuser M, Ganser A. Recombinant human erythropoietin in the treatment of nonrenal anemia. Ann Hematol. 2006;85:69–78
  65. Ludwig H, Fritz E, Leitgeb C, Pecherstorfer M, Samonigg H, Schuster J. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood. 1994;84:1056–1063
  66. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: A systemic, quantitative review. Cancer. 2001;91:2214–2221
  67. Vaupel P, Mayer A. Hypoxia and anemia: effects on tumor biology and treatment resistance. Transfus Clin Biol. 2005;12:5–10
  68. Hockel M, Knoop C, Schlenger K, Vorndran B, Baussmann E, Mitze M, et al. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol. 1993;26:45–50
  69. Kelleher DK, Mattheinsen U, Thews O, Vaupel P. Blood flow, oxygenation, and bioenergetic status of tumors after erythropoietin treatment in normal and anemic rats. Cancer Res. 1996;56:4728–4734
  70. Thews O, Koenig R, Kelleher DK, Kutzner J, Vaupel P. Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia. Br J Cancer. 1998;78:752–756
  71. Silver DF, Piver MS. Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer: A possible oxygen effect. Gynecol Oncol. 1999;73:280–284
  72. Thews O, Kelleher DK, Vaupel P. Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors. Cancer Res. 2001;61:1358–1361
  73. Stuben G, Pottgen C, Knuhmann K, Schmidt K, Stuschke M, Thews O, et al. Erythropoietin restores the anemia-induced reduction in radiosensitivity of experimental human tumors in nude mice. Int J Radiat Oncol Biol Phys. 2003;55:1358–1362

PII: S0037-1963(07)00067-4

doi: 10.1053/j.seminhematol.2007.04.004

Seminars in Hematology
Volume 44, Issue 3 , Pages 157-165 , July 2007

Article Tools

* Image Usage & Resolution